Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Post by BillyBufford155on May 20, 2015 3:43pm
421 Views
Post# 23746311

Knight's Cash Position and Book Value getting attractive

Knight's Cash Position and Book Value getting attractiveGUD has about $450 million cash/marketable securities, $500 Book value and seems to be making some extremely astute allocations of capital in this market. Jonathon Goodman seems to really know what he is doing, and seems to be running GUD on the level of a Warren Buffett or John Malone. I know Warren Buffett said that he will start buying back BRK shares when they drop below 120% Book Value. Well, GUD (at $7/share) with $525 mill. current Book Value X 120% = $675 mill. Currently, the market cap of GUD is around %650 mill so I'm thinking he stock is getting quite attractive for the long term investor IMHO.
Bullboard Posts